01:22 PM EDT, 05/30/2025 (MT Newswires) -- AbCellera Biologics ( ABCL ) said Friday it received authorization from Health Canada to initiate a phase 1 clinical trial of ABCL575, its investigational antibody therapy for moderate-to-severe atopic dermatitis.

The Phase 1 trial, expected to begin in Q3, will evaluate the safety and pharmacokinetics of ABCL575 when administered subcutaneously in healthy participants.

AbCellera said the therapy also has potential applications for other inflammatory and autoimmune conditions.

Shares of AbCellera were down 2.7% in recent trading.

Price: 1.99, Change: -0.05, Percent Change: -2.45